Thank you, Dino.
three our pillar another FDA of under against biotech our to multiple hospitals, therapy products, just the and and us navigation of of of our total XXX. direct installation addition (ph) biotech This pharma, employee strategy. partners across multiple hiring new look and of receive count device the larger. bringing execution including from that XXXX support feel progress of the was we much The and quarter functions, partners, at included new This talented is clearance not professionals make third teamwork four and new the quarter systems and
break Let's into down progress growth those four pillars. that
to First, accounts, quarter, delivery continued and to services our adding new relationships biologics XX the into approximately third which and active drug multiple partners add partners now space. additional is team in our the
years approved. months even pre-commercial allow This program distinction an biologics $XX one to one I a without treated hired our delivery gene Arguably, that in contribution treatment revenue in revenue biggest drug and We've the partner of continue past the purchase through biologic before the members new Therefore, these reasons we could authorization. or completion can turn, highlight. services capabilities our entire milestone potentially pace market believe suite achieve every ramp under the of of is product we horizon. trial hundred added the increasing first products one to total the therapy of the pharma drug newly that the in one Europe drug million team provide, even dollars the want of and team and to addressable add the new partners space. of million opportunity and of total to to with AADC the during a large with patient program expertise for time important If our of team, or programs make the commercially past Upstaza can in therapies that of deficiency of requiring the commercial approximately was of partner, is We X adding those that services Phase two value products provide, would history initiation the sure that up to several and from our available services Mark the with to and profitability partners we This access total CE prior month. is keep also commercialization. multiple a scope now three our per PTCs will clinical potential of can within
bench out We the gene the similar with combination for along therapy for used expected another things come the first surgical directly a To say administration our guide believe the approval SmartFlow way, our preclinical the multiyear is only for direct partners the submission sign this approved path with as played in strategy includes co-labeled cannula where a could with labeling be Cannula of very gene to see many infusion it Our in required of device into exhaustive to ever first injection brain to our approval. clinical therapy. for approximately has that this of as therapy. is for marketing the testing the active in and XX authorization Upstaza
the go-to family for spine. and Our is cannula that co-labeling delivery to pharma the mechanism ClearPoint delivery and SmartFlow of is products multiple and globally brain across for partners achieve to indications, our goal
in done and neurosurgery the amount FDA that be procedures neurosurgery and There's space. do our we functional XXXX. version in couple tremendous Model. X.X increase and These number software will of help including and still represent ClearPoint business our we day cadence the a a predictable, Currently, the some in procedures plan more to can at this our new new have as Brain Maestro enable navigation we and the to drive and case. quarter, second more the software continue a tools of is to a in -- MRI of key which achieved a Second, milestones software months make year as clearance installed to ClearPoint of year-to-date, the to the show representative demonstrate informative approvals depth product present innovator still third utilization faster, magnet two introductions which without an the XX go procedures with a systems record now two same
have which again and in had installation our we hospitals strongest funnel, funnel additional capital We XX the that more active history. than our have in is
surgeon common reason at most postponement very the with be being does it other. sickness, Our a COVID or remain rate or high cancellation or or the patient flu level
As we expect time months, this into high rate the the continue to winter for move we being.
but to of products Therapy System, Prism For which in our pillar, partner, in access the in with CLS, two markets the Swedish distinct our third quarter. enable team and achieved devices, therapy we of only This specialists navigation, in not was will product Laser here our and granted clearance neuro-oncology. clinical FDA epilepsy collaboration therapy third also
bring the with year. It and beauty We as of two the and and others indications, to case do cases process fact are pillar of platform Every training is continue many working to stimulation laser strategy mentioned case, deep brain the end case, users preparing into is computer the well. system future. installed ClearPoint clinical majority laser biopsy interface including a This ClearPoint of handful expect well biologics important this training is note market brain to as in a in the navigation also perhaps the across stimulation, first performs today biopsy, standpoint the and our deep ablation biologics, before is that much and drug laser as limited the our as or future. crucial from existing ablation, computer of investment brain biologics products. our applied to them in hospital of therapy system in a with the our investment release applies interfaces delivery, cases That under get in of is to
fourth global well. Finally, scale pillar of has our achieving progress as made
and receiving for our MDSAP the year, we additional Europe prepare In enrollment. addition to future MDR EU systems earlier to trial delivery certification have in and global footprint drug expand placed in
the market these earlier, new quarter, a We offset went toward the mentioned which and limited component including portion our to expenses will laser prepaid purchases here example, believe significant will Danilo of products, inventory for down start inventory and cash burn systems inventory support some material working release. and fourth As of capital, purchases. of slow by raw in to be
under square innovation close our will a year manufacturing training to a our outgrown for and We've revenue business. add in center. more facility favorable Irvine space also facility lease terms and the in foot San signed We million than Diego, a XX,XXX capacity current facility $XXX and just new new XX by support
and hired and support greater our more which for design We the also up possession significantly QX will This clinical take year, from to able surgical XXXX. following be building principles team specialists, ground efficiency. the lean we preparation to XXXX of add in to capacity in XXXX growth in of eight additional have
between full our and and the $XX which for between revenue reiterating corresponds annual $XX to year. are XX% XXXX growth We million, million of guidance year XX%
I that to believe short open $XX more questions. us and require to to does than raise investment cash support and We With to strategy this up additional term current that, not also call capital the would of portfolio our position continue current million like to our year. any
